Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124,417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Systems Biology Graphical Notation.
Le Novère N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, Demir E, Wegner K, Aladjem MI, Wimalaratne SM, Bergman FT, Gauges R, Ghazal P, Kawaji H, Li L, Matsuoka Y, Villéger A, Boyd SE, Calzone L, Courtot M, Dogrusoz U, Freeman TC, Funahashi A, Ghosh S, Jouraku A, Kim S, Kolpakov F, Luna A, Sahle S, Schmidt E, Watterson S, Wu G, Goryanin I, Kell DB, Sander C, Sauro H, Snoep JL, Kohn K, Kitano H. Le Novère N, et al. Among authors: kim s. Nat Biotechnol. 2009 Aug;27(8):735-41. doi: 10.1038/nbt.1558. Epub 2009 Aug 7. Nat Biotechnol. 2009. PMID: 19668183 Free article.
The bioinformatics of microarray gene expression profiling.
Weinstein JN, Scherf U, Lee JK, Nishizuka S, Gwadry F, Bussey AK, Kim S, Smith LH, Tanabe L, Richman S, Alexander J, Kouros-Mehr H, Maunakea A, Reinhold WC. Weinstein JN, et al. Among authors: kim s. Cytometry. 2002 Jan 1;47(1):46-9. doi: 10.1002/cyto.10041. Cytometry. 2002. PMID: 11774349 Free article. Review. No abstract available.
Corrigendum to "Illudin S inhibits p53-Mdm2 interaction for anticancer efficacy in colorectal cancer" [Biomed. Pharmacother. 182 (2025) 117795].
Lee Y, Lee YY, Park J, Maksakova A, Seo D, Kim J, Yeom JE, Kim Y, Kim CH, Ryoo R, Kim SN, Park J, Park W, Kim TH, Choy YB, Park CG, Kim KH, Lee W. Lee Y, et al. Among authors: kim sn. Biomed Pharmacother. 2025 Jan 10:117810. doi: 10.1016/j.biopha.2025.117810. Online ahead of print. Biomed Pharmacother. 2025. PMID: 39799037 No abstract available.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551-0. Online ahead of print. Lancet. 2025. PMID: 39798579
124,417 results
You have reached the last available page of results. Please see the User Guide for more information.